China Isotope Radiation Corporation (1763) Fair Value & Analysis
Healthcare · HK · Market cap HK$5.7B
Fair value as of: Aug 13, 2026
From 17 valuation models · updated 3 days ago
Fair value updated Aug 13, 2026, revised from HK$25.49 to HK$25.51 (+0.1%) since Aug 5, 2026. Share price +0.4% over the past month.
Below-average quality, screening 49% undervalued on our models.
What matters now
- Solid quality (49/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (HK$15.77 to HK$29.70) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$8.24 – HK$26.83 · fair‑value band HK$15.77 – HK$29.70 · the HK$17.11 price screens below the HK$25.51 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
China Isotope Radiation Corporation (1763) currently trades at HK$17.11, while our model-based Fair Value estimate is HK$25.51, implying the stock looks roughly 49.1% undervalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, China Isotope Radiation Corporation generated revenue of HK$7.2B at a net margin of 4.6%. Revenue declined 9.1% year over year. It earns a return on equity of 8.4%. Net debt stands at HK$134M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$15.77 (bear case) to HK$29.70 (bull case); at HK$17.11, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at 49%, 1763 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Multiples (HK$21.94) versus DCF Models (HK$4.76). Highest evidence: Residual Income (76).
Notify me when 1763 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China.
Full company description
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test diagnostic kits, test analyzers, and other products. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, pharmaceuticals, cosmetics, and food for sterilization, and provides design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Nuclear Medical Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides trade services for nuclear technology industry applications, medical product applications, technical services, and sales of medical devices. This segment also offers independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive sources, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation operates as a subsidiary of China National Nuclear Corporation.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Isotope Radiation Corporation reported revenue of HK$7.0B in FY2025 versus HK$5.1B in FY2021, a compound +8.0%/yr. Reported net income was HK$319M in FY2025, compounding −1.3%/yr from FY2021.
of which total revenue +14.4 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 1763: get an alert when its fair value changes →
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare China Isotope Radiation Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is China Isotope Radiation Corporation (1763) overvalued or undervalued?
What is the fair value of 1763?
What is the quality score of 1763?
What is the revenue of China Isotope Radiation Corporation (1763)?
What is the net profit margin of 1763?
Does China Isotope Radiation Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track China Isotope Radiation Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.